找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Hodgkin Lymphoma; A Comprehensive Over Andreas Engert,Anas Younes Book 2020Latest edition Springer Nature Switzerland AG 2020 Hodgkin Lymph

[復(fù)制鏈接]
樓主: industrious
41#
發(fā)表于 2025-3-28 15:26:45 | 只看該作者
42#
發(fā)表于 2025-3-28 19:59:22 | 只看該作者
Treatment of Early Favorable Hodgkin LymphomaHodgkin lymphoma became highly curable with large radiotherapy fields but at the cost of high early and late toxicity resulting in reduced long-term survival. The successful introduction of multiagent chemotherapy in Hodgkin lymphoma made it possible to combine chemotherapy with radiotherapy in smal
43#
發(fā)表于 2025-3-29 02:30:54 | 只看該作者
Treatment of Early Unfavorable Hodgkin Lymphomatinal mass, extranodal disease, high ESR, or more than three or four nodal areas involved. In addition, selected stage IIB patients are also included in this risk group. The treatment for these patients is based on four cycles of ABVD chemotherapy followed by involved-field radiotherapy or a more ag
44#
發(fā)表于 2025-3-29 03:12:48 | 只看該作者
Treatment of Advanced-Stage Hodgkin Lymphomase within 5 years. Thus, remission rates in excess of 50% achieved with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) were a major breakthrough in oncology when first seen over 40 years ago. Systematic searches for more effective regimens have replaced MOPP by ABVD (doxorubicin,
45#
發(fā)表于 2025-3-29 07:47:28 | 只看該作者
46#
發(fā)表于 2025-3-29 13:21:05 | 只看該作者
Pediatric Hodgkin Lymphomary driving force for this divergence over the last 15–20 years has been a desire to reduce the burden of treatment with particular reference to late effects. That reduction is being achieved primarily by limiting the amount of radiotherapy required to maintain excellent EFS rates. Titration of thera
47#
發(fā)表于 2025-3-29 17:38:14 | 只看該作者
48#
發(fā)表于 2025-3-29 23:47:26 | 只看該作者
49#
發(fā)表于 2025-3-30 02:02:26 | 只看該作者
Henrik Hjalgrim,Ruth F. Jarrettocesses; transition arrays between level ensembles (configurations, superconfigurations); effective temperatures of configurations, superconfigurations, and ions; charge-state distributions; radiative power losses and opacity. There are many numerical examples and comparisons with experiment present
50#
發(fā)表于 2025-3-30 07:48:01 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-13 21:54
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
翁牛特旗| 平山县| 革吉县| 勃利县| 阜南县| 安图县| 威海市| 黄浦区| 喀什市| 盐津县| 三台县| 漳平市| 保定市| 余干县| 攀枝花市| 昭平县| 诸暨市| 加查县| 塔河县| 双流县| 肥乡县| 修水县| 同仁县| 平顶山市| 慈溪市| 瓮安县| 伊春市| 武冈市| 扬州市| 茂名市| 阿克苏市| 浦江县| 大丰市| 东兰县| 上饶县| 宝丰县| 峨山| 凉城县| 九台市| 建水县| 赞皇县|